Y-3 for （）
Phase 1Small molecule
Y-3 for （） is one of 2 small molecule programs targeting Hepatic Insufficiency. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Hepatic Insufficiency
#DrugCompanyPhaseTrials
1Ulonivirine
Merck & Co.Phase 1
Y-3 for （）
NNeurodawn Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Y-3 for （）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details